Abstract
Vaccination is the single most cost effective health intervention in all
countries. The historical market for vaccine products has been relatively small
when compared to the growth of therapeutic products to treat disease. Vaccine
production is capital-intensive, utilizes outdated technology and currently
produces vaccines only for relatively few diseases.
Emerging and new technologies based on advances in immunology, genetics and
molecular biology will address a whole new range of infectious disease and
cancer targets. Future vaccine technologies will provide a highly cost-effective
alternative to conventional treatment, while at the same time creating a higher
profit potential for vaccine products.
Sales of preventive vaccines, once considered a commodity market, are now on
the increase. The vaccine market grew by double-digits between 2000 and 2001,
exceeding the pharmaceutical sector as a whole, which grew only 8.6% in the same
period. The vaccine market has exhibited strong growth since 1999, mainly driven
by new product introductions and the expansion of immunization programs.
Interest in vaccine production is spurred by increased demand for flu
vaccinations, vaccine use by tourists visiting tropical countries, fears of
bioterrorism, and vaccines to combat ongoing sources of widespread epidemics or
pandemics, including malaria, herpes, hepatitis C, and HIV. In addition,
opportunities for vaccine manufacturers are opening in the prevention and
treatment of emerging diseases such as West Nile Virus, ebola, and SARS.
The vaccine R&D pipeline is an indicator of how the breadth of
indications covered and the scope of patient groups targeted is likely to
increase over the next eight to ten years. For example, more than 80
prophylactic products are in development targeting at least twenty diseases, for
which there are currently no marketed vaccines. Volume sales and an associated
demand for production capacity will also increase. This will drive companies to
increase capacity and improve the efficiency of their manufacturing processes.
Scope and Methodology
This report covers pediatric and adult preventive vaccine products and
provides an analysis of therapeutic vaccines for cancer treatment.. In assessing
the market for vaccine products, Kalorama Information provides sales data for
the 2001-2003 historical years, the 2004 base year, and the 2001 through 2010
forecast years. Revenues are expressed in terms of manufacturers annual sales
and in current U.S. dollars.
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Telephone interviews and email correspondence were the primary method of
gathering information. For the purpose of this study, Kalorama Information
conducted interviews with key industry officials, consultants, health care
providers, and government personnel. These sources were the primary basis in
gathering information specifically relating to revenue and market share data
presented in this report. Specific interviews with pharmaceutical company
representatives included marketing directors, division managers, and product
representatives.
Pediatric vaccines include the following:
- Combination vaccines
- Diphtheria-tetanus-pertussis (DTP) and diphtheria-tetanus-acellular
pertussis (DTaP)
- Hepatits A; Hepatitis B
- Measles-mumps-rubella (MMR)
- Pneumococcal
- Poliovirus
- Varicella
- Others
Adult vaccines include the following:
- Hepatitis A; Hepatitis B
- Influenza
- Pneunomoccal
- Travel; DT; others
| 
View Cart
